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Background: Use of intracoronary calcium channel blockers (CCBs) during percutaneous 
coronary intervention (PCI) has been shown to have favorable effects on coronary blood ﬂ  ow. 
We aimed to investigate the effects of CCBs administrated perorally on creatine kinase-MB 
(CK-MB) levels in patients undergoing elective PCI.
Methods: A total of 570 patients who underwent PCI were evaluated for CK-MB elevation. 
Patients who were on CCB therapy when admitted to the hospital constituted the CCB group. No 
CCBs were given to the rest of the patients during the periprocedural period and these patients 
served as the control group. Blood samples for CK-MB were obtained before and at 6 h, 24 h, 
and 36 h after the procedure.
Results: 217 patients were in the CCB group (mean age 60.2 ± 9.3 years, 162 males), and 
353 were in the control group (mean age 60.0 ± 10.1 years, 262 males). CK-MB levels increased 
above the normal values in 41 patients (18.9%) of the CCBs group and in 97 patients (27.5%) 
of the control group (p = 0.02). Median CK-MB levels were signiﬁ  cantly higher in the control 
group for all studied hours (for all p  0.05).
Conclusions: Prior oral CCB therapy may have favorable effects in preventing myocyte 
necrosis after elective PCI.
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Introduction
Elevation of creatine kinase-MB (CK-MB) isoenzyme due to myonecrosis after 
elective percutaneous coronary intervention (PCI) can be detected in 5%–30% 
of patients (Abdelmeguid and Topol 1996; Califf et al 1998; Simoons et al 1999; 
Tardiff et al 1999; Akkerhuis et al 2002). Factors related to the procedure such as 
side-branch occlusion, intimal dissection, and distal embolization have been sug-
gested as possible causes of increased cardiac enzymes after PCI (Abdelmeguid 
et al 1996; Simoons et al 1999; Tardiff et al 1999). Other possible mechanisms are 
coronary vasospasm and no re-ﬂ  ow phenomenon (Demir et al 2002). Several studies 
have reported that elevated cardiac markers such as CK-MB and cardiac troponins 
(cTn) after PCI is associated with an increase in cardiac mortality and morbidity 
during follow-up (Abdelmeguid et al 1996; Califf et al 1998; Simoons et al 1999; 
Tardiff et al 1999).
Previous studies suggested intracoronary administration of calcium channel 
blockers (CCBs) is effective for resolving coronary spasm and no-reﬂ  ow phenomenon 
(Michaels et al 2002; Werner et al 2002). To our knowledge there is no data about the 
effects of administration of oral CCBs on CK-MB levels after PCI.
The aim of this study was to investigate the effect of CCBs used perorally on 
CK-MB levels in patients undergoing elective PCI.Vascular Health and Risk Management 2008:4(6) 1418
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Methods
Patient population and study protocol
The study was approved by the local Ethics Committee of 
Baskent University Hospital in Ankara, Turkey. All patients 
undergoing PCI between December 2000 and December 
2005 at our institution were evaluated for eligibility for this 
study, and all provided written informed consent before 
participating. Patients who were taking a CCB at the dis-
cretion of their own primary physician on admission were 
noted and the drug at the same dose was continued during 
the hospitalization period and thereafter. No CCBs were 
prescribed to the patients who were not already on one. 
Patients presenting with acute or recent myocardial infarc-
tion (MI) within 7 days, renal insufﬁ  ciency with creatinine 
levels higher than 1.4 mg/dL, and those in whom use of a 
special device (laser, rotational atherectomy, brachy-therapy, 
etc) was planned were excluded. A total of 570 patients with 
elective PCI history were included in the study (mean age 
60.1 ± 9.8 years, 74.4% males). The patients who were on 
a CCB on admission constituted the CCB group while the 
others served as controls.
There were 217 patients (mean age 60.2 ± 9.3 years, 
74.7% males) in the CCB group and 353 patients (mean 
age 60.0 ± 10.1 years, 74.2% males) in the control group. 
Ninety percent of the patients in the CCB group were receiv-
ing diltiazem 180 mg/day, whereas others were receiving 
amlodipine 10 mg/day, felodipine 4 mg/day, or verapamil 
240 mg/day.
All interventions were performed via the femoral 
approach. The choices of technique (percutaneous translu-
minal coronary angioplasty [PTCA], PTCA + stent, stent 
only) and adjunctive pharmacologic management were at 
the discretion of the operator according to the lesion char-
acteristics. Angiographic success was deﬁ  ned as a residual 
stenosis of the treated lesion 50% on visual estimation 
and -in case of stenting- desired position of the stent with 
Thrombolysis in Myocardial Infarction grade III ﬂ  ow. Com-
mercially available drug-eluting and bare metal stents were 
used. All patients received aspirin 300 mg/day, and 75-mg 
maintance dose of clopidogrel.
Laboratory analyses
Creatine kinase-MB isoform was measured routinely before 
PCI and 6, 24, and 36 h after PCI. Additional measure-
ments were done for clinical indications. Levels of CK-MB 
were determined by an immunoinhibition assay (Roche 
Diagnostics, GmbH, Mannheim, Germany). The reference 
limit for CK-MB with this method is 0–24 U/L. CK-MB 
levels were considered elevated if the measurement was 
above the normal limit in any of the follow-up measure-
ments. The CK-MB levels were further subdivided into 
1 to 3 times (24–72 U/l) and 3 to 5 times (73–120 U/l) of 
the normal levels.
Statistical analysis
The statistical package, SPSS version 9.0 (SSPS Inc., Chicago, 
IL, USA) was used for statistical analyses. Continuous 
variables with normal distribution were compared using 
the unpaired Student’s t-test and were presented as the 
mean ± SD. Continuous variables with abnormal distribu-
tions were compared using the Mann-Whitney U test, and 
CK-MB results for each group were expressed as median and 
interquartile ranges. The CK-MB elevation within the groups 
were compared with the general lineer model for repeated 
measures test. Categorical data were reported as frequencies 
and percentages. Comparisons between categorical variables 
were performed using Fisher exact tests if any subgroup 
consisted of ﬁ  ve or fewer items; otherwise, chi-square tests 
were used. Values for p less than 0.05 were considered 
statistically signiﬁ  cant.
Results
Baseline clinical and laboratory characteristics were similar 
between two groups (Table 1). The angiographic and proce-
dural characteristics of the patients are listed in Table 2. No 
differences were observed between the groups (all p  0.05). 
No patients died during the study period. Major adverse 
effects which included coronary artery spasm or dissection, 
the need for blood transfusion and subacute occlusion were 
not different between the groups (Table 2).
Baseline CK-MB levels were similar in patients in the 
CBB and control groups (Table 3). During in-hospital follow-
up period for 36 hours, CK-MB levels increased above the 
normal values in 41 patients (18.9%) of the CCBs group 
and in 97 patients (27.5%) of the control group (p = 0.02). 
The incidence of CK-MB elevation 1 to 3 times normal 
was 18.9% vs 26.9% (p = 0.03); 3 to 5 times normal was 
0.5% vs 3.1% (p = 0.03) in the CCB and control groups, 
respectively. Three patients (0.8%) in the control group and 
none in the CCB group had CK-MB levels 5 times normal 
(p = 0.29). The diagnosis of postprocedural MI was based 
on either an increase in CK-MB 3 times the upper limit of 
normal, or development of pathologic Q waves in 2 or more 
contiguous electrocardiographic leads.
The median CK-MB levels were signiﬁ  cantly higher 
in the control group compared with CCBs group at 6 h, Vascular Health and Risk Management 2008:4(6) 1419
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Table 1 Baseline clinical and laboratory features of CCB and control groups
CCB group 
n = 217
Control group 
n = 353
P value
Clinical characteristics
 Age (year) 60.2 ± 9.3 60.0 ± 10.1 0.79
  Sex, male, n (%) 162 (74.7) 262 (74.2) 0.90
  SAP/USAP, n (%) 140 (64.5)/77 (35.5) 232 (65.7)/121 (34.3) 0.77
  Diabetes mellitus, n (%) 50 (23.0) 102 (28.9) 0.14
  Hypertension, n (%) 137 (63.1) 193 (54.7) 0.05
  Dyslipidemia, n (%) 135 (62.2) 217 (61.5) 0.67
  Smoking, n (%) 92 (42.4) 142 (40.2) 0.78
  History of PCI, n (%) 49 (22.6) 53 (15.0) 0.05
  History of CABG, n (%) 43 (19.8) 58 (16.4) 0.33
  Mean LVEF, % 47 ± 11 48 ± 12 0.69
Drugs
 ACE inhibitors, n (%) 73 (33.6) 149 (42.2) 0.05
  Statins, n (%) 134 (61.8) 228 (64.6) 0.49
  Nitrates, n (%) 66 (30.4) 131 (37.1) 0.11
Laboratory Findings
  Fasting blood sugar levels (mg/dL) 111.9 ± 42.2 115.3 ± 45.6 0.45
  Blood urea nitrogen levels (mg/dL) 17.9 ± 5.9 18.3 ± 6.5 0.65
 Creatinine  (mg/dL) 1.1 ± 0.8 1.1 ± 0.6 0.99
  LDL cholesterol (mg/dL) 112.3 ± 39.3 111.3 ± 38.6 0.79
 Triglyceride (mg/dL) 154.5 ± 76.6 164.5 ± 94.5 0.28
  Hemoglobin (g/dL) 14.1 ± 1.6 13.7 ± 1.7 0.06
Abbreviations: CCB, calcium channel blocker; PCI, percutaneous coronary interventions; CABG, coronary artery bypass graft surgery; LVEF, left ventricular ejection fraction; 
SAP, stable angina pectoris; USAP, unstable angina pectoris; ACE, angiotensin-converting enzyme; LDL, low-density lipoprotein.
Table 2 Details of PCI procedures between groups
 CCB  group 
n = 217
Control group 
n = 353
P value
Dilated coronary artery
  Left anterior descending, n (%) 89 (41.0) 174 (49.3) 0.05
 Left  circumﬂ  ex, n (%) 79 (36.4) 118 (33.4) 0.46
  Right coronary artery, n (%) 74 (34.1) 100 (28.3) 0.15
  Graft lesion, n (%) 13.0 (6.0) 13 (3.7) 0.19
  Multi-vessel PCI, n (%) 41 (18.9) 60 (17.0) 0.56
Drug-eluting stent, n (%) 5 (2.3) 11 (3.1) 0.79
Stent used per procedure, n (%) 1.3 ± 0.4 1.3 ± 0.4 0.77
Mean stent length (mm) 13.3 ± 6.5 13.3 ± 6.7 0.92
Mean stent diameter (mm) 2.9 ± 0.4 3.0 ± 0.4 0.16
Total inﬂ  ation time, s 124.2 ± 85.7 114.8 ± 83.3 0.23
Max inﬂ  ation pressure, atm 11.8 ± 5.4 11.8 ± 4.1 0.99
Spasm, n (%) 6 (2.8) 6 (1.7) 0.39
Dissections, n (%) 3 (1.4) 6 (1.7) 1.00
Blood transfusion, n (%) 2 (0.9) 3 (0.8) 1.00
Subacute occlusion, n (%) 5 (2.3) 7 (2.9) 0.77
Abbreviations: CCB, calcium channel blockers; CK-MB, creatine kinase-MB; PCI, percutaneous coronary interventions.Vascular Health and Risk Management 2008:4(6) 1420
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24 h, 36 h after PCI (Table 3). The elevations of CK-MB 
levels were statistically signiﬁ  cant within the groups (both 
p  0.001) (Figure 1).
Discussion
Both previous retrospective studies and prospective random-
ized trials have shown that development of new treatment 
strategies like intracoronary nitrate infusion, oral statins, 
glycoprotein IIb/IIIa inhibitors and adenosine reduce isch-
emic complications, death, nonfatal myocardial infarction, 
and release of CK-MB after coronary interventions when 
compared with placebo (EPISTENT 1998; Kurz et al 2000; 
Desmet et al 2002; Hermann et al 2002; Aronow et al 2002a, 
2002b; Wang et al 2003; Pasceri et al 2004). Moreover, 
recently published trials demonstrated beneﬁ  cial effects of 
beta blockers on CK-MB levels in patients with PCI as well 
(Roberts et al 1991; Sharma et al 2000; Ellis et al 2001; Wang 
et al 2003; Sato et al 2004).
Several studies have shown that intracoronary 
administration of CCBs reduces procedural myonecro-
sis in patients undergoing elective or urgent PCI. Demir 
and colleagues (2002) and Werner and colleagues (2002) 
have reported that intracoronary verapamil has favourable 
effects on coronary vasospasm and no-reﬂ  ow phenomenon 
in patients with primary PTCA for acute MI. In VAPOR 
(VAsodilator Prevention On no-Reflow) trial intragraft 
verapamil was given pre-PCI to prevent no-reﬂ  ow and 
there was a trend toward improved myocardial perfusion 
as assessed using the TIMI myocardial perfusion grade 
(TMPG) (Michaels et al 2002). In the VESPA (VErapamil 
Slow-Release for Prevention of Cardiovascular Events After 
Angioplasty) trial, 240 mg/d verapamil administered for 
six months after PCI reduced the incidence of need for repeat 
target vessel revascularization (Bestehorn et al 2004). A new 
recent meta-analysis of the two largest trials, Nisoldipine in 
Coronary artery Disease in Leuven (NICOLE) and Coronary 
Table 3 Median (interquartile range) CK-MB levels of the groups during follow-up
CCB group n = 217 Control group n = 353 P value
Baseline CK-MB, U/L 11.0 (7.0–16.0) 12.0 (8.0–17.0) 0.13
After PCI, 6th hours CK-MB, U/L 14.0 (8.2–21.0) 15 (10.2–21.0) 0.03
After PCI, 24th hours CK-MB, U/L 13.0 (9.0–19.7) 16.0 (11.0–22.0) 0.001
After PCI, 36th hours CK-MB, U/L 13.0 (8.0–20.0) 15.0 (10.0–24.0) 0.000
Abbreviations: CCB, calcium channel blockers; CK-MB, creatine kinase-MB; PCI, percutaneous coronary interventions.
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Figure 1 Mean CK-MB levels of the groups during follow-up.
Abbreviations: CCB, calcium channel blockers; CK-MB, creatine kinase-MB.Vascular Health and Risk Management 2008:4(6) 1421
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Angioplasty Amlodipine in Restenosis Study (CAPARES), 
found that CCBs improved long term clinical outcome and 
reduced the need for target vessel revascularization when 
compared with placebo (Dens et al 2003). It was concluded 
that this might be due to the antiproliferative properties of 
CCBs which were demonstrated in in vitro experiments (Yang 
et al 1993; Voisard et al 1997). Moreover, the recently pub-
lished trial by Matthews and colleagues (2005) demonstrated 
that using intracoronary CCB at the time of PCI result in 
lower postprocedural creatine phosphokinase (CPK) values 
and smaller areas under the CPK curve.
The aim of our study was to evaluate the relationship 
between systemic administration of CCBs and the elevation 
of CK-MB suggestive of myonecrosis. The results indicate 
that in elective PCI, per procedural CCBs usage may be 
associated with reduced CK-MB release. The cardioprotec-
tive effects of CCBs’ observed in our study can be explained 
by several mechanisms.
Klein and colleagues (1989) have found that the devel-
opment of infarcts were signiﬁ  cantly delayed and the mean 
infarct sizes were smaller with intracoronary infusion of 
diltiazem, verapamil or nifedipine indicating that CCBs 
increase the ischemic tolerance signiﬁ  cantly by their effects 
on calcium homeostasis in the setting of acute ischemia 
during baloon inﬂ  ations at PCI.
The CCBs may also protect the patients against fatal or 
nonfatal infarction via their platelet-inhibiting effects. Folts 
(1997) have reported that IV amlodipine administration 
was found to be protective against exacarbation of coronary 
thrombosis by epinephrine in dog model of experimental 
coronary artery thrombosis.
CCBs’ may also improve nitric oxide (NO) release 
and improve endothelial functions (Taddei et al 2001). 
The ENCORE Investigators (Evaluation of Nifedipine and 
Cerivastatin on Recovery of Coronary Endothelial function) 
have reported that 30 to 60 mg/d nifedipine treatment over 
a 6 month period improved coronary endothelial function 
in the most constricted segment. Mechanisms that could 
be targeted by CCBs’ include antioxidative properties and 
effects on endothelial nitric oxide synthase (eNOS) expres-
sion and activity (ENCORE 2003). The present study was 
not designed to evaluate the mechanism by which CCBs 
might prevent myonecrosis after PCI and we do not know 
the factors affecting our results.
Study limitations
There are several limitations of this study. This study is 
a nonrandomized study with lack of clinical follow-up. 
The patient numbers in the present study are small and lack 
the ability of a prospective randomized trial to minimize 
differences between the groups. The groups were formed 
before the study and the patients who were receiving CCBs 
at the discretion of their physician constituted the drug group, 
so the patients used different types and doses of CCBs. We 
did not collect any data on myocardial perfusion by angi-
ography (TIMI frame count, myocardial perfusion blush 
scores), dynamic ST-segment changes to identify a relation 
with no-reﬂ  ow at any time during mechanical perfusion. The 
number of patients with CK-MB elevations in both groups 
was small, and all patients at both groups had a very low 
incidence of MI after PCI.
Conclusion
Despite these limitations, the study points out that systemic 
administration of CCBs may be associated with reduced 
CK-MB release after elective PCIs. Long-term prospective 
randomized trials are required to conﬁ  rm the effects of CCBs 
on myocyte necrosis in patients undergoing elective PCI.
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